Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Lilly To Seek EUA For Olumiant

Plus: Gilead Agrees European Procurement Deal On Veklury

Executive Summary

Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.

You may also be interested in...



Lilly Gets Second EUA, For Baricitinib In COVID-19 Patients

Weeks after FDA authorized emergency use of its antibody bamlanivimab, Lilly’s RA drug Olumiant can be used to shorten recovery time for hospitalized COVID-19 patients in the US. Authorizations are being pursued elsewhere as well.

Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant

It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.  

Lilly Seeks EUA For COVID-19 Antibody, Unveils Positive Combo Data

Following last month’s data showing reduced hospitalization risk with single neutralizing antibody therapy, Lilly now has data showing a two-antibody combo reduces COVID-19 viral load significantly.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel